Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.

Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P

Diabetes care27 Jan 2021Cited by 54 (Europe PMC)

PMID33504496PMCIDPMC7985419DOI10.2337/dc20-1622PepBankPUB-33504496

Source link PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes and high cardiovascular risk (LEADER trial, irrespective of treatment), a UACR reduction above 30% at 1 year was linked to a lower risk of MACE than any increase in UACR.
In plain wordsIn adults with type 2 diabetes, a large fall in urine albumin in the first year was linked to fewer heart events, whatever the treatment.
Peptide
Liraglutide
Outcome
DecreaseMACE risk, UACR reduction above 30% versus any increase
Study
n: not reported in source
Comparator
Any increase in UACR
Outcome group
Cardiovascular events · Cardiovascular
Measurements
hazard ratio
0.82 ratio
UACR reduction >30% vs any increase, MACE
Source sentences
Summary
For MACE, hazard ratios (HRs) for those with >30% and 30-0% UACR reduction were 0.82 (95% CI 0.71, 0.94; P = 0.006) and 0.99 (0.82, 1.19; P = 0.912), respectively, compared with any increase in UACR (reference).
2 context sentences(design, population, supporting numbers)
Summary · context
LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5-5 years in 9,340 participants with type 2 diabetes and high cardiovascular risk.
Summary · context
We calculated change in urinary albumin-to-creatinine ratio (UACR) from baseline to 1 year in participants with >30% reduction (n = 2,928), 30-0% reduction (n = 1,218), or any increase in UACR (n = 4,124), irrespective of treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3350449601
02HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes and high cardiovascular risk (LEADER trial, irrespective of treatment), a UACR reduction of 30-0% at 1 year was not linked to a different MACE risk than any increase in UACR.
In plain wordsIn adults with type 2 diabetes, a small fall in urine albumin in year one was not linked to a different risk of heart events.
Peptide
Liraglutide
Outcome
No significant changeMACE risk, UACR reduction 30-0% versus any increase
Study
n: not reported in source
Comparator
Any increase in UACR
Outcome group
Cardiovascular events · Cardiovascular
Measurements
hazard ratio
0.99 ratio
UACR reduction 30-0% vs any increase, MACE
Source sentences
Summary
For MACE, hazard ratios (HRs) for those with >30% and 30-0% UACR reduction were 0.82 (95% CI 0.71, 0.94; P = 0.006) and 0.99 (0.82, 1.19; P = 0.912), respectively, compared with any increase in UACR (reference).
2 context sentences(design, population, supporting numbers)
Summary · context
LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5-5 years in 9,340 participants with type 2 diabetes and high cardiovascular risk.
Summary · context
We calculated change in urinary albumin-to-creatinine ratio (UACR) from baseline to 1 year in participants with >30% reduction (n = 2,928), 30-0% reduction (n = 1,218), or any increase in UACR (n = 4,124), irrespective of treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3350449602
03HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes and high cardiovascular risk (LEADER trial, irrespective of treatment), a UACR reduction above 30% at 1 year was linked to a lower risk of the composite nephropathy outcome than any increase.
In plain wordsIn adults with type 2 diabetes, a large fall in urine albumin in the first year was linked to fewer kidney problems, whatever the treatment.
Peptide
Liraglutide
Outcome
DecreaseComposite nephropathy outcome, UACR reduction above 30% versus any increase
Study
n: not reported in source
Comparator
Any increase in UACR
Outcome group
Kidney function · Kidney and urinary
Measurements
hazard ratio
0.67 ratio
UACR reduction >30% vs any increase, nephropathy
Source sentences
Summary
For the composite nephropathy outcome, respective HRs were 0.67 (0.49, 0.93; P = 0.02) and 0.97 (0.66, 1.43; P = 0.881).
2 context sentences(design, population, supporting numbers)
Summary · context
LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5-5 years in 9,340 participants with type 2 diabetes and high cardiovascular risk.
Summary · context
We calculated change in urinary albumin-to-creatinine ratio (UACR) from baseline to 1 year in participants with >30% reduction (n = 2,928), 30-0% reduction (n = 1,218), or any increase in UACR (n = 4,124), irrespective of treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3350449603
04HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes and high cardiovascular risk (LEADER trial, irrespective of treatment), a UACR reduction of 30-0% at 1 year was not linked to a different risk of the composite nephropathy outcome than any increase.
In plain wordsIn adults with type 2 diabetes, a small fall in urine albumin in year one was not linked to a different risk of kidney problems.
Peptide
Liraglutide
Outcome
No significant changeComposite nephropathy outcome, UACR reduction 30-0% versus any increase
Study
n: not reported in source
Comparator
Any increase in UACR
Outcome group
Kidney function · Kidney and urinary
Measurements
hazard ratio
0.97 ratio
UACR reduction 30-0% vs any increase, nephropathy
Source sentences
Summary
For the composite nephropathy outcome, respective HRs were 0.67 (0.49, 0.93; P = 0.02) and 0.97 (0.66, 1.43; P = 0.881).
2 context sentences(design, population, supporting numbers)
Summary · context
LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5-5 years in 9,340 participants with type 2 diabetes and high cardiovascular risk.
Summary · context
We calculated change in urinary albumin-to-creatinine ratio (UACR) from baseline to 1 year in participants with >30% reduction (n = 2,928), 30-0% reduction (n = 1,218), or any increase in UACR (n = 4,124), irrespective of treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3350449604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.